

06-05-00

A

Express Mail Label No. EI748253158US

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)*(Only for new nonprovisional applications under 37 CFR 1.53(b))*Docket No.
P02142Total Pages in this Submission
234**TO THE ASSISTANT COMMISSIONER FOR PATENTS**Box Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

SURFACE TREATMENT OF MEDICAL DEVICE

and invented by:

Jay F. Kunzler, David E. Seelye, Joseph C. SalamoneIf a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Enclosed are:

Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 28 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☐ Cross References to Related Applications *(if applicable)*
 - c. ☐ Statement Regarding Federally-sponsored Research/Development *(if applicable)*
 - d. ☐ Reference to Microfiche Appendix *(if applicable)*
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☒ Brief Description of the Drawings *(if drawings filed)*
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
P02142

Total Pages in this Submission
234

Application Elements (Continued)

3. ☒ Drawing(s) (when necessary as prescribed by 35 USC 113)
- a. ☒ Formal Number of Sheets 2
- b. ☐ Informal Number of Sheets _____
4. ☒ Oath or Declaration
- a. ☒ Newly executed (original or copy) ☐ Unexecuted
- b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
- d. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (usable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under
Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby
incorporated by reference therein.
6. ☐ Computer Program in Microfiche (Appendix)
7. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
- a. ☐ Paper Copy
- b. ☐ Computer Readable Copy (identical to computer copy)
- c. ☐ Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. ☒ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(B) Statement (when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure Statement/PTO-1449 ☒ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
- ☐ First Class ☒ Express Mail (Specify Label No.): EI748253158US

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
P02142

Total Pages in this Submission
234

Accompanying Application Parts (Continued)


15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☐ Additional Enclosures (please identify below):

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	20	- 20 =	0	x \$18.00	\$0.00
Indep. Claims	3	- 3 =	0	x \$78.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$690.00
OTHER FEE (specify purpose) Assignment					\$40.00
TOTAL FILING FEE					\$730.00

- ☐ A check in the amount of _____ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. 02-1425 as described below. A duplicate copy of this sheet is enclosed.
- ☒ Charge the amount of \$730.00 as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).


Signature

Robert B. Furr, Jr.
Registration No. 32,985
Bausch & Lomb Incorporated
One Bausch & Lomb Place
Rochester, New York 14604
Telephone: 716/338-6530

Dated:

cc:

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): Jay F. Kunzler, David E. Seelye, Joseph C. Salamone

Docket No.

P02142

Serial No.

Not Yet Assigned

Filing Date

June 2, 2000

Examiner

Not Yet Assigned

Group Art Unit

Not Yet Assigned

Invention: SURFACE TREATMENT OF MEDICAL DEVICE

10835 U.S. PTO
09/586941
06/02/00

I hereby certify that this New Utility Patent Application Transmittal Letter and its Attachments
(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under
37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on
June 2, 2000
(Date)

Sharon L. Sechrist

(Typed or Printed Name of Person Mailing Correspondence)



(Signature of Person Mailing Correspondence)

EI748253158US

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.

FIELD OF THE INVENTION

Medical devices such as ophthalmic lenses made from silicone-containing materials have been investigated for a number of years. Such materials can generally be subdivided into two major classes, namely hydrogels and non-hydrogels. Non-hydrogels do not absorb appreciable amounts of water, whereas hydrogels can absorb and retain water in an equilibrium state. Regardless of their water content, both non-hydrogel and hydrogel silicone medical devices tend to have relatively hydrophobic, non-wettable surfaces that have a high affinity for lipids. This problem is of particular concern with contact lenses.

BACKGROUND

Those skilled in the art have long recognized the need for modifying the surface of such silicone contact lenses so that they are compatible with the eye. It is known that increased hydrophilicity of the contact lens surface improves the wettability of the contact lenses. This in turn is associated with improved wear comfort of contact lenses. Additionally, the surface of the lens can affect the lens's susceptibility to deposition, particularly the deposition of proteins and lipids from the tear fluid during lens wear. Accumulated deposition can cause eye discomfort or even inflammation. In the case of extended wear lenses (i.e. lenses used without daily removal of the lens before sleep), the surface is especially important, since extended wear lens must be designed for high standards of comfort and biocompatibility over an extended period of time.

Silicone lenses have been subjected to plasma surface treatment to improve their surface properties, e.g., surfaces have been rendered more hydrophilic, deposit resistant, scratch-resistant, or otherwise modified. Examples of previously disclosed plasma

surface treatments include subjecting contact lens surfaces to a plasma comprising an inert gas or oxygen (see, for example, U.S. Patent Nos. 4,055,378; 4,122,942; and 4,214,014); various hydrocarbon monomers (see, for example, U.S. Patent No. 4,143,949); and combinations of oxidizing agents and hydrocarbons such as water and ethanol (see, for example, WO 95/04609 and U.S. Patent No 4,632,844). U.S. Patent No. 4,312,575 to Peyman et al. discloses a process for providing a barrier coating on a silicone or polyurethane lens by subjecting the lens to an electrical glow discharge (plasma) process conducted by first subjecting the lens to a hydrocarbon atmosphere followed by subjecting the lens to oxygen during flow discharge, thereby increasing the hydrophilicity of the lens surface.

U.S. Patents 4,168,112, 4,321,261 and 4,436,730, all issued to Ellis et al., disclose methods for treating a charged contact lens surface with an oppositely charged ionic polymer to form a polyelectrolyte complex on the lens surface that improves wettability.

U.S. Patent 4,287,175 to Katz discloses a method of wetting a contact lens that comprises inserting a water-soluble solid polymer into the cul-de-sac of the eye. The disclosed polymers include cellulose derivatives, acrylates and natural products such as gelatin, pectins and starch derivatives.

U.S. Patent 5,397,848 to Yang et al. discloses a method of incorporating hydrophilic constituents into silicone polymer materials for use in contact and intra-ocular lenses.

U.S. Patents 5,700,559 and 5,807,636, both to Sheu et al., discloses hydrophilic articles (for example, contact lenses) comprising a substrate, an ionic polymeric layer on the substrate and a disordered polyelectrolyte coating ionically bonded to the polymeric layer.

U.S. Patent 5,705,583 to Bowers et al. discloses biocompatible polymeric surface coatings. The polymeric surface coatings disclosed include coatings synthesized from monomers bearing a center of positive charge, including cationic and zwitterionic monomers.

European Patent Application EP 0 963 761 A1 discloses biomedical devices with coating that are said to be stable, hydrophilic and antimicrobial, and which are formed

using a coupling agent to bond a carboxyl-containing hydrophilic coating to the surface by ester or amide linkages.

Thus, it is desired to provide a silicone hydrogel contact lens with an optically clear, hydrophilic surface film that will not only exhibit improved wettability, but which will generally allow the use of a silicone hydrogel contact lens in the human eye for extended period of time. In the case of a silicone hydrogel lens for extended wear, it would be desirable to provide a contact lens with a surface that is also highly permeable to oxygen and water. Such a surface treated lens would be comfortable to wear in actual use and would allow for the extended wear of the lens without irritation or other adverse effects to the cornea. It would be desirable to manufacture such a surface treated lens without the need for an oxidation step such as plasma treatment or corona discharge treatment.

SUMMARY OF THE INVENTION

The present invention is directed to a method for improving the wettability of a medical device, comprising the steps of:

- (a) providing a medical device formed from a monomer mixture comprising a hydrophilic monomer and a silicone-containing monomer, wherein said medical device has not been subjected to a surface oxidation treatment, and
- (b) contacting a surface of the medical device with a solution including a polymer or copolymer of (meth)acrylic acid, whereby the polymer or copolymers of meth(acrylic) acid forms a complex with the hydrophilic monomer on the contact lens surface without a surface oxidation treatment step and without the addition of a coupling agent.

In a preferred embodiment, the meth(acrylic) acid polymer or copolymer comprises acid content of at least 40 mole percent, more preferably at least about 50 mole percent.

The method of the invention requires neither surface oxidation treatment step nor the addition of a coupling agent. The term "coupling agent" means an entity other than the medical device or the hydrophilic coating material that forms a linkage between the

surface of the medical device and the hydrophilic coating material. Examples of linkages provided by coupling agents include ester linkages and amide linkages.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows the relationship of lens diameter and water content (weight percent) to poly(acrylic acid) (PAA) concentration for the substrate material identified as RD 677 in Example 1.

FIG. 2 shows the dependence of lens diameter (y-axis) upon the concentration of poly(acrylamide-co-acrylic acid) for the surface treatment of the substrate material RD1077 in separate experiments using different concentrations of poly(acrylamide-co-acrylic acid) as shown in Table 6.

DETAILED DESCRIPTION OF THE INVENTION

As mentioned above, the present invention is directed to a silicone hydrogel contact lens having a coating and a method of manufacturing the same, which coating improves the hydrophilicity and lipid resistance of the lens. The poly(acrylic) acid complexation coating allows a lens that could otherwise not be comfortably worn in the eye to be worn in the eye for an extended period of time, for example, more than 24 hours at a time.

The method of the present invention is useful with biocompatible materials including both soft and rigid materials commonly used for ophthalmic lenses, including contact lenses. The preferred substrates are hydrogel materials, including silicone hydrogel materials. Particularly preferred materials include vinyl functionalized polydimethylsiloxanes copolymerized with hydrophilic monomers as well as fluorinated methacrylates and methacrylate functionalized fluorinated polyethylene oxides copolymerized with hydrophilic monomers.

Examples of substrate materials useful in the present invention are taught in U.S. Patents 5,908,906 to Kunzler et al.; 5,714,557 to Kunzler et al.; 5,710,302 to Kunzler et al.; 5,708,094 to Lai et al.; 5,616,757 to Bambury et al.; 5,610,252 to Bambury et al.; 5,512,205 to Lai; 5,449,729 to Lai; 5,387,662 to Kunzler et al. and 5,310,779 to Lai; which patents are incorporated by reference as if set forth at length herein.

The invention provides a method for the preparation of wettable silicone-based hydrogel formulations utilizing a poly(acrylic) acid (PAA) surface complexation. Silicone hydrogel formulations containing hydrophilic polymers, such as polydimethylacrylamide or polyvinylpyrrolidinone, are treated with water-based solutions containing PAA or PAA co-polymers to render a lubricious, stable, highly wettable PAA-based surface coating. The treatment is performed at room temperature or under autoclave conditions. No additional oxidative surface treatment such as corona discharge or plasma oxidation is required. No separate coupling agent as described herein is required. The mechanism of this treatment is presently believed to be a surface complexation reaction between PAA and vinylpyrrolidone groups on the lens surface that occurs through a hydrogen bonding mechanism.


Surface coating materials useful in the present invention include P(vinylpyrrolidinone(VP)-co-acrylic acid(AA)), P(methylvinylether-alt-maleic acid), P(acrylic acid-graft-ethyleneoxide), P(acrylic acid-co-methacrylic acid), P(acrylamide-co-AA), P(acrylamide-co-AA), P(AA-co-maleic), and P(butadiene-maleic acid).

Coating materials preferred for use in the present invention include those polymers containing carboxylic acid functionality. Particularly preferred polymers are characterized by acid contents of at least about 30 mole percent, preferably at least about 40 mole percent.

The invention is applicable to a wide variety of materials, and silicone hydrogel contact lens materials are particularly preferred. Hydrogels in general are a well-known class of materials that comprise hydrated, cross-linked polymeric systems containing water in an equilibrium state. Silicone hydrogels generally have a water content greater than about 5 weight percent and more commonly between about 10 to about 80 weight percent. Such materials are usually prepared by polymerizing a mixture containing at least one silicone-containing monomer and at least one hydrophilic monomer. Typically, either the silicone-containing monomer or the hydrophilic monomer functions as a crosslinking agent (a crosslinker being defined as a monomer having multiple polymerizable functionalities) or a separate crosslinker may be employed. Applicable silicone-containing monomeric units for use in the formation of silicone hydrogels are well known in the art and numerous examples are provided in U.S. Patent Nos.

4,136,250; 4,153,641; 4,740,533; 5,034,461; 5,070,215; 5,260,000; 5,310,779; and 5,358,995.

Examples of applicable silicon-containing monomeric units include bulky polysiloxanylalkyl (meth)acrylic monomers. An example of bulky polysiloxanylalkyl (meth)acrylic monomers are represented by the following Formula I:




(I)

wherein:

X denotes -O- or -NR-;

each R₁ independently denotes hydrogen or methyl;

each R₂ independently denotes a lower alkyl radical, phenyl radical or a group represented by




wherein each R'₂, independently denotes a lower alkyl or phenyl radical; and h is 1 to 10.

Some preferred bulky monomers are methacryloxypropyl tris(trimethylsiloxy)silane or tris(trimethylsiloxy)silylpropyl methacrylate, sometimes referred to as TRIS.

Another class of representative silicon-containing monomers includes silicone-containing vinyl carbonate or vinyl carbamate monomers such as: 1,3-bis[4-vinyloxycarbonyloxy)but-1-yl]tetramethyl-disiloxane; 3-(trimethylsilyl)propyl vinyl carbonate; 3-(vinyloxycarbonylthio)propyl-[tris(trimethylsiloxy)silane]; 3-[tris(trimethylsiloxy)silyl] propyl vinyl carbamate; 3-[tris(trimethylsiloxy)silyl] propyl allyl

carbamate; 3-[tris(trimethylsiloxy)silyl]propyl vinyl carbonate; t-butyltrimethylsiloxyethyl vinyl carbonate; trimethylsilylethyl vinyl carbonate; and trimethylsilylmethyl vinyl carbonate.

An example of silicon-containing vinyl carbonate or vinyl carbamate monomers are represented by Formula II:



wherein:




Y' denotes -O-, -S- or -NH-;


R^{Si} denotes a silicone-containing organic radical;

R₃ denotes hydrogen or methyl;


d is 1, 2, 3 or 4; and q is 0 or 1.

Suitable silicone-containing organic radicals R^{Si} include the following:






and



wherein:

R_5 denotes




wherein p' is 1 to 6;

R_5 denotes an alkyl radical or a fluoroalkyl radical having 1 to 6 carbon atoms;

e is 1 to 200; n' is 1, 2, 3 or 4; and m' is 0, 1, 2, 3, 4 or 5.


An example of a particular species within Formula II is represented by Formula III.



(III)

Another class of silicon-containing monomers includes polyurethane-polysiloxane macromonomers (also sometimes referred to as prepolymers), which may have hard-soft-hard blocks like traditional urethane elastomers. They may be end-capped

with a hydrophilic monomer such as HEMA. Examples of such silicone urethanes are disclosed in a variety of publications, including Lai, Yu-Chin, "The Role of Bulky Polysiloxanylalkyl Methacrylates in Polyurethane-Polysiloxane Hydrogels," *Journal of Applied Polymer Science*, Vol. 60, 1193-1199 (1996). PCT Published Application No. WO 96/31792 discloses examples of such monomers, which disclosure is hereby incorporated by reference in its entirety. Further examples of silicone urethane monomers are represented by Formulae IV and V:



wherein:


D denotes an alkyl diradical, an alkyl cycloalkyl diradical, a cycloalkyl diradical, an aryl diradical or an alkylaryl diradical having 6 to 30 carbon atoms;

G denotes an alkyl diradical, a cycloalkyl diradical, an alkyl cycloalkyl diradical, an aryl diradical or an alkylaryl diradical having 1 to 40 carbon atoms and which may contain ether, thio or amine linkages in the main chain;

* denotes a urethane or ureido linkage;

a is at least 1;

A denotes a divalent polymeric radical of Formula VI:




wherein:

each R_s independently denotes an alkyl or fluoro-substituted alkyl group having 1 to 10 carbon atoms which may contain ether linkages between carbon atoms;

m' is at least 1; and

p is a number which provides a moiety weight of 400 to 10,000;

each of E and E' independently denotes a polymerizable unsaturated organic radical represented by Formula VII:



(VII)

wherein:

R_6 is hydrogen or methyl;

R_7 is hydrogen, an alkyl radical having 1 to 6 carbon atoms, or a $-\text{CO}-\text{Y}-\text{R}_9$ radical wherein Y is $-\text{O}-$, $-\text{S}-$ or $-\text{NH}-$;

R_8 is a divalent alkylene radical having 1 to 10 carbon atoms;

R_9 is a alkyl radical having 1 to 12 carbon atoms;


X denotes $-\text{CO}-$ or $-\text{OCO}-$;

Z denotes $-\text{O}-$ or $-\text{NH}-$;

Ar denotes an aromatic radical having 6 to 30 carbon atoms;


w is 0 to 6; x is 0 or 1; y is 0 or 1; and z is 0 or 1.

A more specific example of a silicone-containing urethane monomer is represented by Formula (VIII):



(VIII)

wherein m is at least 1 and is preferably 3 or 4, a is at least 1 and preferably is 1, p is a number which provides a moiety weight of 400 to 10,000 and is preferably at least 30, R₁₀ is a diradical of a diisocyanate after removal of the isocyanate group, such as the diradical of isophorone diisocyanate, and each E" is a group represented by:



A preferred silicone hydrogel material comprises (in the bulk monomer mixture that is copolymerized) 5 to 50 percent, preferably 10 to 25, by weight of one or more silicone macromonomers, 5 to 75 percent, preferably 30 to 60 percent, by weight of one or more polysiloxanylalkyl (meth)acrylic monomers, and 10 to 50 percent, preferably 20 to 40 percent, by weight of a hydrophilic monomer. In general, the silicone macromonomer is a poly(organosiloxane) capped with an unsaturated group at two or more ends of the molecule. In addition to the end groups in the above structural formulas, U.S. Patent No. 4,153,641 to Deichert et al. discloses additional unsaturated groups, including acryloxy or methacryloxy. Fumarate-containing materials such as those taught in U.S. Patents 5,512,205; 5,449,729; and 5,310,779 to Lai are also useful

substrates in accordance with the invention. Preferably, the silane macromonomer is a silicon-containing vinyl carbonate or vinyl carbamate or a polyurethane-polysiloxane having one or more hard-soft-hard blocks and end-capped with a hydrophilic monomer.

Suitable hydrophilic monomers include those monomers that, once polymerized, can form a complex with poly(acrylic acid). The suitable monomers form hydrogels useful in the present invention and include, for example, monomers that form complexes with poly(acrylic acid) and its derivatives. Examples of useful monomers include amides such as dimethylacrylamide, dimethylmethacrylamide, cyclic lactams such as n-vinyl-2-pyrrolidone and poly(alkene glycols) functionalized with polymerizable groups. Examples of useful functionalized poly(alkene glycols) include poly(diethylene glycols) of varying chain length containing monomethacrylate or dimethacrylate end caps. In a preferred embodiment, the poly(alkene glycol) polymer contains at least two alkene glycol monomeric units. Still further examples are the hydrophilic vinyl carbonate or vinyl carbamate monomers disclosed in U.S. Patent Nos. 5,070,215, and the hydrophilic oxazolone monomers disclosed in U.S. Patent No. 4,910,277. Other suitable hydrophilic monomers will be apparent to one skilled in the art.

In particular regard to contact lenses, the fluorination of certain monomers used in the formation of silicone hydrogels has been indicated to reduce the accumulation of deposits on contact lenses made therefrom, as described in U.S. Pat. Nos. 4,954,587, 5,079,319 and 5,010,141. Moreover, the use of silicone-containing monomers having certain fluorinated side groups, i.e. $-(CF_2)_n-H$, have been found to improve compatibility between the hydrophilic and silicone-containing monomeric units, as described in U.S. Pat. Nos. 5,387,662 and 5,321,108.

Solvents useful in the surface treatment (contacting) step of the present invention include solvents that readily solubilize proton donating solutes such as carboxylic acids, sulfonic acids, fumaric acid, maleic acids, anhydrides such as maleic anhydride and functionalized alcohols such as vinyl alcohol. Preferred solvents include tetrahydrofuran (THF), acetonitrile, N,N-dimethyl formamide (DMF), and water. The most preferred solvent is water.

The surface treatment solution is preferably acidified before the contact step. The pH of the solution is suitably less than 7, preferably less than 5 and more preferably less than 4. In a particularly preferred embodiment, the pH of the solution is about 3.5. For a

discussion of the theory underlying the role of pH in complexation reactions in general, see *Advances in Polymer Science*, published by Springer-Verlag, Editor H.J. Cantow, et al, V45, 1982, pages 17-63.

EXAMPLES

Several silicone hydrogel lens formulations were treated, in separate experiments, with a 0.1% PAA, 1.0% PAA and a 0.25% Carbopol solutions. Carbopol is a lightly cross-linked poly(acrylic acid) ("PAA"). The reported molecular weights of the PAA and Carbopol are 450,000 and 2,500,000, respectively.

The samples designated below as RD677 and RD1077 are vynagels. U.S. Patent 5,616,757 to Bambury et al. teaches methods for making vynagel contact lens materials. The samples designated below as RD954 are fluorogels. U.S. Patent 5,710,302 to Kunzler et al. teaches methods for making fluorogel contact lens materials. The samples designated below as RD933 are fumarates. U.S. Patents 5,496,871, 5,449,729, and 5,420,324 teach methods for making fumarate contact lens materials.

Example 1

The surface treatment consists of immersing the lenses in the PAA solution followed by a 30-minute autoclave cycle. The complexation surface treatment of the invention is also effective at room temperature. The lenses are then rinsed in distilled water and re-autoclaved in a suitable buffer, for example a borate buffer.

Excellent wetting characteristics were achieved for this procedure (Table 1). A significant reduction in sessile drop contact angle was observed for both the RD954 (fluorogel) and the RD677 (vynagel) lenses. Inspection of lenses using a cosmetic comparator (Bendix 10x cosmetic comparator Model 10) gives a clarity of 2 for the 1% and 0.1% PAA treated Vynagel lenses and a clarity of 4 for the 0.25% treated Carbopol lenses. The clarity scale for the cosmetic comparator used in the present example is 0 for opaque to 5 for optimum clarity. A value of 2 is an acceptable rating for contact lens applications. Minimal change in water content, lens diameter and mechanical properties were observed following the PAA or Carbopol treatment. Table 1 presents these results.

Table 1
Mechanical and Physical Property Results
For PAA and Carbopol Treated Vynagel and Fluorogel Lenses

Material	Treatment	Modulus	Diameter	Clarity	% Water	Contact Angle		Lipid deposition (ug)	Protein deposition (ug)
						before	after		
RD677 (vynagel)	test 0.25% carbopol	115	14.274	4	38.7	110	65		
	test 0.1% PAA	115	14.229	2	38	110	67		
	test 1.0% PAA	150	14.293	2/3	39.7	110	50	51	26.7
	control RD677	110	13.969	4	35.2	110		402	0
RD954 (fluorogel)	1.0% celanex cast					105	42		
	1.0% polypropylene cast					101	57		
RD1077 (vynagel) (low acid-no plasma)	Control	99	13.82		38.7				
	0.1% P(AA)	93			41.8				
	450K								
	0.05%		14		na				
		PAA Conc.	Diameter	% Water					
		0	13.82	35.2					
		0.1	14.229	38					
		1	14.293	39.7					

Example 2 – Stability of Surface Treatment

A stability study comparing PAA treated lenses was completed. Results are shown in Table 3. RD677 and RD 954 lenses were placed in an 85°C oven for 7 days (to simulate a one-year shelf life) and 17 days (to simulate a three-year shelf-life). The lenses were then removed from the oven and measured for water and isopropanol content. Test and control lenses gave identical results for percentage water loss and percentage weight loss following the 7- and 17-day test period. The combined data showed that the surface complexation had little effect on the overall stability of the lenses. The IPA follow-up extraction measured water insoluble degradation-by-products. The results of Example 2 are shown below in Table 2.

Table 2

PAA stability Autoclave Treatment Material	Control/Test [PAA]	Baseline		7 day 85C		17 day 85C		Baseline	7 day 85C		17 day 85C
		% water	% IPA loss	% water	% IPA	% water	% IPA		mod.	mod.	
RD933	Control	33.7	2.8	37.1	2.4	35.6	2.2				
	0.10% control	36.6	2.1	37.8	1.8	36.3	2.3				
Fluorogel 40 (RD954)	0.10% control	48.1	4.9	52.1	4.6	49.2	4.5				
	0.10% control	48.8	3.2	50.7	3	48.3	8				
Vynagel (RD677)	control	36.9	4.6	40.5	2.7	39	3.1				
	0.10% 1%	35.4	2.4	39.5	2.1	38.2	3				
		40.3	1.7	39.7	2.6	38	2.3				
D5-1077-1185 low acid no plasma	0.1 control	41.8	0.5	42.5	2.2	42.2	1.5	93	139	147	
		38.7	0.7	39.8	2.1	39.8	1.5	99	117	129	

Examples 3 and 4

Tables 3 and 4 provide a list of acid containing polymers that were used in the complexation of RD677 (vynagel). This summary provides data for both the autoclave treatment and a sonication treatment. For the sonication step, the lenses are placed in a beaker containing the polymer solution and sonicated for two hours at a temperature between room temperature and about 40°C using a Branson Model 5200 sonicator.

Tables 3 and 4 also list the wetting and lubricity characteristics of the treated lenses. The sonication method consists of immersing the lenses in the polymer solution and sonicating the lenses at room temperature for two hours. This procedure offers the advantage that lenses can be surface treated at the lens processing step (following extraction and prior to cosmetic inspection). In the autoclave procedure, the vials need to be re-opened, re-extracted in distilled water and re-autoclaved in borate prior to use.

002093 7469360

Table 3

Complexation	Complexation via autoclave treatment				
Lens Material	Polymer (0.1% solution unless noted)	Conditions	Surface characteristics	Diameter	
RD677 test lens	PVP-co-AA (25%) 96K (0.05%)	auto	fair wetting/no lubricity	14.241	
	PVP-co-AA (25%) 96K (0.1%)	auto	fair wetting/no lubricity	14.213	
	MVE-alt-MA 1.98M (0.05%)	auto	fair wetting/no lubricity	14.183	
	MVE-alt-MA 1.98M (0.1%)	auto	fair wetting/no lubricity	14.145	
	PAA-sodium-graft PEO acidified to 3 (0.05%)	auto	fair wetting/marginal lub	14.209	
	PAA-sodium-graft PEO acidified to 3 (0.1%)	auto	fair wetting/marginal lubricity	14.145	
	P(acrylamide-co-acrylic acid) 200K acidified 30/70 (0.05)	auto	excellent wetting/lubricity	14.308	
	P(acrylamide-co-acrylic acid) 200K acidified 30/70 (0.1)	auto	excellent wetting/lubricity	na	
	Carbopol 940 (0.05%)	auto	excellent wetting/lubricity	na	
	Carbopol 940 (0.1%)	auto	good wetting/fair lubricity	14.166	
RD677 control lens	borate buffer	auto	no wetting or lubricity	14.195	

Table 4

Complexation

Lens Material	Polymer (0.1% solution unless noted)	Conditions	Surface characteristics	Diameter
RD677 test lens	P(vinylpyrrolidinone(VP)-co-acrylic acid(AA)) (25%AA) 96K	balsonic 2hrs	good wetting/lubricious	14.213
	P(methylvinylether-alt-maleic acid) 1.98M	balsonic 2hrs	good wetting/fair lubricity	14.183
	P(acrylic acid-graft-ethyleneoxide)	balsonic 2hrs	good wetting/fair lubricity	14.145
	P(acrylic acid-co-methacrylic acid 34K	balsonic 2hrs	fair wetting/fair lubricity	
	P(acrylamide-co-AA) Mw 200K 10% AA	balsonic 2hrs	poor wetting/no lubricity	
	P(acrylamide-co-AA Mw 200K 1.5% AA	balsonic 2hrs	poor wetting/no lubricity	
	P(AA) 4M	balsonic 2hrs	good wetting/lubricious	
	P(AA-co-maleic) to ph3 70K	balsonic 2hrs	excellent wetting and lubricity	
	P(AA) followed by PVP 1% Mw 1.3M	balsonic 2hrs	no wetting/no lubricity	
	P(AA) followed by imidazolidinone 1% solution	balsonic 2hrs	no wetting/no lubricity	
	P(maleic acid) polyscience	balsonic 2hrs	poor wetting/no lubricity	
	P(butadiene-maleic acid (polyscience)	balsonic 2hrs	good wetting/fair lubricity	
	P(acrylamide-co-acrylic acid 200K acidified 30/70	balsonic 2hrs	excellent wetting and lubricity	
	1% pvp	balsonic 2hrs	no wetting/no lubricity	
	940 (0.1%)	balsonic 2hrs	good wetting/lubricity	14.166
RD677 control lens	borate buffer	balsonic 2hrs	no wetting/no lubricity	14

Tables 5 and 6 show the sonication and autoclave treatment results for material RD1077. Similar wetting and lubricity characteristics were achieved. Figure 3 shows the dependence of lens diameter versus concentration of the poly(acrylamide-co-acrylic acid) solution.

Table 5

Complexation

Lens Material	Polymer and concentration	Conditions	Surface characteristics (11/06/98)	Diameter	Clarity
RD1077 test lens	PVP-co-AA (25%) 96K (1.0)	autoclave	light haze, excellent wetting, lubricity	14.196	2
	0.1	autoclave	clear, poor wetting	14.06	4
	0.05	autoclave	good clarity, lubricity and wetting	13.92	
	MVE-alt-MA 1.98M (1.0)	autoclave	slight haze, excellent wetting, lubricity	14.14	
	0.1	autoclave	slight haze, excellent wetting	14.03	
	0.05	autoclave	slight haze, excellent wetting, lubricity	13.95	
	PAA-sodium-graft PEO acidified to 3 (0.1)	autoclave	good clarity, no wetting, no lubricity	na	
		autoclave	na	na	
	P(acrylamide-co-acrylic acid) 200K acidified 90/10 (1.0)	autoclave	clear, good wetting, no lubricity	13.12	
	0.1	autoclave	poor wetting, no lubricity	13.7	
	0.05	autoclave	poor wetting, no lubricity	13.85	
	P(acrylamide-co-acrylic acid) 200K acidified 60/40 (1.0)	autoclave	clear, excellent wetting, fragile	13	2
	0.1	autoclave	clear, excellent wetting, fragile	13.98	2
	0.05	autoclave	slight haze, wets well, lubricious	14.12	2
	P(acrylamide-co-acrylic acid) 200K acidified 30/70 (1.0)	autoclave	clear, good wetting, lubricious	14.12	4
	0.1	autoclave	clear, good wetting, lubricious	14.19	4
	0.05	autoclave	clear, good wetting, lubricious	14.09	4
	Carpopol 940 (0.1%)	autoclave	light haze, excellent wetting, lubricious	13.92	2
	0.05	autoclave	very good wetting, marginal lubricity	14.01	4
	P(AA) 4M (0.1)	autoclave	light haze, good wetting, lubricious	13.98	1
	0.05	autoclave	good wetting, marginal lubricity	13.92	3
RD1077 control lens	borate buffer	autoclave	no wetting or lubricity	13.8	

Table 6

Complexation

Lens Material	Polymer and concentration	Conditions	Surface characteristics	Clarity	Diameter
RD1077					
no plasma	PVP-co-AA (25%) 96K (1.0)	2 hr sonication	light haze, excellent wetting and lubricity	3	14.14
	0.1	2 hr sonication	clear, poor wetting	5	14.03
	0.05	2 hr sonication	good clarity, marginal lubricity and wetting		14.02
	MVE-alt-MA 1.98M (1.0)	2 hr sonication	light haze, excellent wetting and lubricity	3	13.786
	0.1	2 hr sonication	light haze, excellent wetting and lubricity		14.065
	0.05	2 hr sonication	light haze, excellent wetting and lubricity		14.084
	PAA-sodium-graft PEO acidified to 3 (0.1)	2 hr sonication	good clarity, no wetting, no lubricity		na
		2 hr sonication	na		na
	polyacrylamide-co-acrylic acid 200K acidified 90/10 (1.0)	2 hr sonication	clear, good wetting, no lubricity		13
	0.1	2 hr sonication	poor wetting, no lubricity		13.14
	0.05	2 hr sonication	poor wetting, no lubricity		13.85
	polyacrylamide-co-acrylic acid 200K acidified 60/40	2 hr sonication	clear, excellent wetting, fragile	3	prec.
	0.1	2 hr sonication	clear, excellent wetting, fragile	3	na
	0.05	2 hr sonication	light haze, excellent wetting and lubricity		13.73
	polyacrylamide-co-acrylic acid 200K acidified 30/70 (1.0)	2 hr sonication	clear, good wetting, lubricious	4	14.15
	0.1	2 hr sonication	clear, good wetting, lubricious	3	14.075
	0.05	2 hr sonication	clear, good wetting, lubricious	2	na
	940 (0.1%)	2 hr sonication	light haze, excellent wetting, lubricity	4	14.18
	0.05	2 hr sonication	very good wetting, marginal lubricity	4	13.6
	P(AA) 4M (0.1%)	2 hr sonication	light haze, good wetting, lubricious	4	14.06
	0.05	2 hr sonication	good wetting, marginal lubricity	4	14.05
RD1077control lens	borate buffer	2 hr sonication	no wetting or lubricity	4	13.8
	note: wetting and lub=lubricious				

CLAIMS

1. A method for improving the wettability of a medical device, comprising the steps of:
 - (a) providing a medical device formed from a monomer mixture comprising a hydrophilic monomer and a silicone-containing monomer, wherein said medical device has not been subjected to a surface oxidation treatment;
 - (b) contacting a surface of the medical device with a solution comprising a proton-donating wetting agent, whereby the wetting agent forms a complex with the hydrophilic monomer on the surface of the medical device in the absence of a surface oxidation treatment step and without the addition of a coupling agent.
2. The method of claim 1 wherein said wetting agent solution comprises at least one polymer containing carboxylic acid functionality.
3. The method of claim 1, wherein the proton-donating wetting agent is selected from the group consisting of carboxylic acids, sulfonic acids, fumaric acids, maleic acids, anhydrides, and vinyl alcohols.
4. The method of claim 1, wherein the medical device comprises in bulk formula 5 to 75 percent by weight of one or more silicone macromonomers and 5 to 75 percent by weight of a hydrophilic monomer.
5. The method of claim 4, wherein the hydrophilic monomer is selected from the group consisting of unsaturated carboxylic acids, vinyl lactams, acrylamides, vinyl carbonate or vinyl carbamate, oxazolone monomers, and mixtures thereof.
6. The method of claim 4, wherein the hydrophilic monomer is selected from the group consisting of methacrylic and acrylic acids, 2-hydroxyethylmethacrylate, N-vinylpyrrolidone, methacrylamide, N,N-dimethylacrylamide, and mixtures thereof.

15. The method of claim 1 wherein said medical device is an ophthalmic lens.

16. The method of claim 15 wherein said ophthalmic lens is a contact lens.

17. The method of claim 16 wherein said contact lens is a silicone hydrogel lens.

18. The method of claim 15 wherein said contact lens is a rigid-gas-permeable lens.

19. A method for improving the wettability of a medical device comprising the steps of:

(a) providing a medical device comprising a silicone-containing monomer and at least one other monomer selected from the group consisting of poly(n-vinyl pyrrolidone) and poly(dimethylacrylamide), wherein said medical device has not been subjected to a surface oxidation treatment; and

(b) contacting a surface of the medical device with a solution comprising at least one selected from the group consisting of poly(acrylic acid) and poly(acrylic acid-co-acrylamide).

20. The method of claim 19 further comprising acidifying said solution of step (b) to provide a solution pH of less than 5.

SURFACE TREATMENT OF MEDICAL DEVICE

ABSTRACT

The invention provides a method for improving the wettability of a medical device, comprising the steps of:

- (a) providing a medical device formed from a monomer mixture comprising a hydrophilic monomer and a silicone-containing monomer, wherein said medical device has not been subjected to a surface oxidation treatment;
- (b) contacting a surface of the medical device with a solution comprising a proton-donating wetting agent, whereby the wetting agent forms a complex with the hydrophilic monomer on the surface of the medical device in the absence of a surface oxidation treatment step and without the addition of a coupling agent.




Figure 1. Dependence of lens diameter and water content on P(AA) concentration for RD677

091215344.050200




Figure 2. Dependence of Diameter versus Poly(acrylamide-co-acrylic acid) concentration

092325944.050200

Attorney's Docket No. P02142

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is of the following type:

- provisional
- x original
- design
- divisional
- continuation
- continuation-in-part (CIP)

INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

SURFACE TREATMENT OF MEDICAL DEVICE

the specification of which is attached hereto.

ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

- x In compliance with this duty, there is attached an information disclosure statement. 37 CFR 1.97.

PRIORITY CLAIM (35 U.S.C. §119)

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the same application(s) of which priority is claimed.

- x no such applications have been filed.
such applications have been filed as follows:

PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. §119

Country	Application Number	Date of Filing (day, month, year)

**CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)
UNDER 35 U.S.C. 120**

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior applications(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national filing date of this application.

		Status (check one)	
U.S. Applications	U.S. Filing Date	Patented	Pending
1. 0/			
2. 0/			

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

U.S. Applications	U.S. Filing Date
1.	
2.	

POWER OF ATTORNEY

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Robert B. Furr, Jr., Registration No. 32,985
William Greener, Registration No. 38,165
Craig E. Larson, Registration No. 27,917
Katherine McGuire, Registration No. 33,537
Mark Montgomery, Registration No. 42,827
Denis A. Polyn, Registration No. 27,152
Michael L. Smith, Registration No. 35,685
John E. Thomas, Registration No. 34,070
Rita D. Vacca, Registration No. 33,624

Send correspondence to:

Direct telephone calls to:

Robert B. Furr, Jr.
Law Department
Bausch & Lomb Incorporated
One Bausch & Lomb Place
Rochester, NY 14604

(716) 338-6530


DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application of any patent issued thereon.

SIGNATURE(S)

Full name of first inventor Jay F. Künzler

Inventor's signature



Date 6/1/00


Country of Citizenship US

Residence: 6020 Monks Road, Canandaigua, New York 14424

Post Office Address: Same as above

Full name of second inventor David E. Seelye

Inventor's signature



Date 1 June 2000

Country of Citizenship US

Residence: P O Box 356, North Chili, New York 14514

Post Office Address: Same as above

002090 "T1598560

Country of Citizenship US